Compare USAS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | NVCR |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | USAS | NVCR |
|---|---|---|
| Price | $5.77 | $12.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.08 | ★ $28.42 |
| AVG Volume (30 Days) | ★ 3.5M | 1.8M |
| Earning Date | 11-10-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $104,867,000.00 | ★ $642,269,000.00 |
| Revenue This Year | $22.65 | $9.75 |
| Revenue Next Year | $69.86 | $5.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $0.87 | $10.70 |
| 52 Week High | $5.90 | $34.13 |
| Indicator | USAS | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 77.11 | 56.12 |
| Support Level | $4.45 | $10.79 |
| Resistance Level | $4.81 | $13.94 |
| Average True Range (ATR) | 0.31 | 0.61 |
| MACD | 0.15 | 0.20 |
| Stochastic Oscillator | 91.42 | 69.68 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.